DeepMed Research

Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Biological Therapy in Treating Patients With Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00039299

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Biological: dendritic cell-MART-1 peptide vaccine
Procedure: leukapheresis

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00005617

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Pancreatic Cancer
Prostate Cancer
Esophageal Cancer
Kidney Cancer
Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00004879

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: vinorelbine ditartrate

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 14

Registration Number: NCT00003963

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2020-09-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 58

Registration Number: NCT00049257

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 44

Registration Number: NCT00039273

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer
Malignant Mesothelioma
Metastatic Cancer
Thymoma and Thymic Carcinoma

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00024076

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Vaccine Therapy in Treating Patients With Liver Cancer

Phase 1

Completed

Conditions: Liver Cancer

Interventions: Biological: AFP

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 33

Registration Number: NCT00022334

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: irinotecan hydrochloride
Drug: paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 51

Registration Number: NCT00020761

Locations: 🇺🇸
OHSU Cancer Institute, Portland, Oregon, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 1 locations

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: Docetaxel
Biological: trastuxumab
Drug: carboplatin

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 263

Registration Number: NCT00047255

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy